Home › Head and Neck Squamous Cell Carcinoma › Virginia
Head and Neck Squamous Cell Carcinoma clinical trials in Virginia
49 studies for Head and Neck Squamous Cell Carcinoma are looking for participants at sites in Virginia.
Cities in Virginia
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
RecruitingPhase 2
Ages 18 to 79 · All sexes · Updated Nov 12, 2026 · NCT04671667BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Inova Alexandria Hospital, Alexandria
- Inova Schar Cancer Institute, Fairfax
- Inova Fair Oaks Hospital, Fairfax
- and 6 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT05136196Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06589804A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
- NEXT Texas LLC - Virginia, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07503808High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
- Peninsula Cancer Institute-Newport News, Newport News
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06992427A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
- University of Virginia, Charlottesville
- Virginia Cancer Specialists, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT06385080A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
- University of Virginia, Charlottesville
- Virginia Cancer Specialists, Fairfax
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07276399JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
- University of Virginia, Charlottesville
- Macon Joan Brock Virginia Health Sciences Eastern Virginia Medical Group at Old Dominion University, Norfolk
RecruitingPhase 3
Ages 60 and older · All sexes · Updated Nov 3, 2026 · NCT04892173CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
- Clinical Study Site, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT07909031A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- Oncology & Hematology Associates of Southwest Virginia, Roanoke
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT03526835FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
- University of Virginia (Site#0134), Charlottesville
- Virginia Commonwealth University (VCU) Massey Cancer Center (Site #0129), Richmond
- Richmond Department of Veterans Affairs (Site #0138), Richmond
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT06788990DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- USA05-0, Virginia Beach
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT06953089A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- NEXT Oncology, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT07109726Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)
- VCU Massey Comprehensive Cancer Center, Richmond
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT06295731A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors
- NEXT Oncology Virginia, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT06747585A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Virginia Cancer Specialists, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT06330064Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
- VCU Massey Comprehensive Cancer Center, Richmond
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT06980038A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
- NEXT Virginia, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT07730021Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic
- NEXT Oncology Virginia, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 23, 2026 · NCT07807345A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Inova Schar Cancer Institute, Fairfax
- Virginia Commonwealth University Massey Cancer Center, Richmond
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT06769698A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Research Site 102, Fairfax
- Research Site 112, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 21, 2026 · NCT05914116Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- Inova Schar Cancer Institute - Fairfax - Innovation Park Drive /ID# 262771, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 14, 2026 · NCT06084481A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC
- Site US073, Roanoke
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT07807163Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- NEXT, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT06993844A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
- UVA Health - Emily Couric Clinical Cancer Center, Charlottesville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 8, 2026 · NCT07768189A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Research Site, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 8, 2026 · NCT07115043Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #66, Charlottesville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT05176483A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
- Site 04, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07814248A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
- ALX Center 2, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07085091Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Virginia Cancer Specialists, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05983432Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
- VCU Community Memorial Health Center, South Hill
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT02734537A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT07182149Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT06532279A Study of DM005 in Patients With Advanced Solid Tumors
- NEXT Oncology Virginia, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT06515990A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- NEXT Virginia, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT05208762First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- USO-Virginia Cancer Specialists, PC, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 7, 2026 · NCT05768139A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Virginia Cancer Specialists, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 6, 2026 · NCT04389632Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Virginia Cancer Specialists - Fairfax /ID# 232592, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 23, 2026 · NCT05005403A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
- GSK Investigational Site, Fredericksburg
- GSK Investigational Site, Wytheville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated May 26, 2026 · NCT06256588Enhancing Oral Cancer Awareness
- Virginia Commonwealth University, Richmond
RecruitingHealthy volunteers welcome
Ages 18 and older · All sexes · Updated May 8, 2026 · NCT06682494From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.